Novo Nordisk (NOVOB.DK) shares are gaining 3.0% after the company raised its sales forecast for 2023 on strong demand for Ozempic and Wegovy medicines.
- Operating profit at constant exchange rates +40% to +46%, previously expected +31% to +37%, Bloomberg estimated +37.5%
- Sales at constant exchange rates +32% to +38%, previously expected +27% to +33%, Bloomberg estimated +31.7%.
Stock of the Month: Will Meta win the AI race?
AMD rises on the wave of the OpenAI deal. Pre-market trading shows a 25% increase in shares.
DE40: France pulls the market lower 📉
Daily Summary: US2000 leads on Wall Street📈Crypto and metals up, US dollar down